TNFSF10 and neoplasm: Pre-clinical investigations have revealed that the utility of the soluble (s) and also full-length (FL) form of TRAIL in animal models could inhibit the proliferation of TRAIL-sensitive human tumor xenografts without any serious systemic toxicity, sustaining the potent application of TRAIL in vivo (23–25).